Poster 1 presents Early Access Program (EAP) data for 111 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.Poster 2 details the Phase 2b randomized, double-blinded study evaluating MaaT033 to enhance overall survival in allogenic hematopoietic cell transplantation patients.For the seventh conse.
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Data, which were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2022, includes results of 81 patients with gastrointestinal acute Graft-versus-Host Disease
Data, which were previously presented at the American Society of Hematology (ASH) Annual Meeting in December 2022, includes results of 81 patients with gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) treated with MaaT013 as part of a compassionate use program in France, and results of the Phase 1b CIMON.
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.